应用药物利用评价和药物利用评估法评价非小细胞肺癌术后化疗病人的用药情况

Evaluation of medication in postoperative chemotherapy patients with non-small cell lung cancer through drug use evaluation and drug use review

目的:评价非小细胞肺癌(non-small cell lung cancer,NSCLC)术后化疗病人的用药情况,为临床合理用药提供参考。方法:采用药物利用评价和药物利用评估法,对116例接受术后化疗的NSCLC病人的药物治疗方案、药物利用情况、治疗过程监测、药物不良反应(ADRs)进行回顾性分析。结果:116例病人共使用8种化疗方案。在化疗辅助用药中,药物利用指数>1的有10种药物。统计的ADRs发生43例次。结论:应加强对NSCLC术后化疗病人的药物治疗过程监测,注意合并用药的选择与个别化疗辅助用药的使用。

Objective： To evaluate medication in postoperative chemotherapy patients with non-small cell lung cancer （NSCLC）, so as to provide evidence for rational application of drugs clinically. Methods： The chemotherapy regimen, drug utilization, therapeutic process monitoring and adverse drug reactions （ADRs） in 116 postoperative chemotherapy patients were retrospectively analyzed with the methods of drug use evaluation （DUE） and drug use review （DUR）. Results： Eight kinds of regimens were used in the treatment of 116 patients. In adiuvant chemotherapy drugs, there were 10 drugs with the drug utilization index （DUI） of more than 1. And 43 ADRs cases were recorded. Conclusion： Further efforts should be made on the therapeutic process monitoring in postoperative chemotherapy patients with NSCLC, the selection of drug combination, and the application of certain adjuvant chemotherapy drugs.